Title of article :
Influence of Randomized Clinical Trial on Practice by Participating Investigators: Lessons From the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)
Author/Authors :
Nowamagbe A. Omoigui MD MPH، نويسنده , , FACC، نويسنده , , Mitchell J. Silver DO، نويسنده , , Lis A. Rybicki MS، نويسنده , , Monique Rosenthal، نويسنده , , Lis G. Berdan PA-C MHS، نويسنده , , Karen Pieper MS، نويسنده , , Samuel V. King MD، نويسنده , , Robert M. Califf MD FACC، نويسنده , , Eric J. Topol MD FACC، نويسنده , , for the CAVEAT I and II Investigators، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 1998
Pages :
8
From page :
265
To page :
272
Abstract :
Objectives. We sought to determine whether the results of the first Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) influenced subsequent practice patterns among the investigators. Background. CAVEAT-I demonstrated that directional coronary atherectomy (DCA) resulted in higher rates of early complications at higher cost and with no clinical benefit. We sought to determine whether these results influenced subsequent use of procedures among CAVEAT-I investigators. Methods. We compared the results of week-long registry of all coronary interventions performed at 35 CAVEAT-I sites in 1994 with those of similar registry obtained in 1992 before the trial, the results of which were published in 1993. For control purposes, the use of procedures was studied at 24 additional sites to provide insight into practice at hospitals not participating in the trial. total of 1,465 interventions were analyzed. Results. Ninety-four percent of CAVEAT-I sites responded. Utilization rates differed between CAVEAT-I and CAVEAT-I follow-up (p < 0.001). Balloon angioplasty decreased from 83.8% to 68.5%, DC increased slightly from 10.7% to 14.1%, and the use of other devices increased from 5.4% to 17.5%. Stand-alone balloon use was more prevalent at nonparticipating control sites than at sites that took part in CAVEAT-I (p < 0.001). Conclusions. Paradoxically, despite the negative findings of CAVEAT-I, there was noteworthy trend toward an increase in the use of DC and other devices at CAVEAT-I sites. Our findings suggest that among investigators in the trial, there may have been lack of influence of trial dat on clinical practice patterns 1 year after publication of the results. Ethics of protocol: Both CAVEAT I and II were approved by the Institutional Review Board at each study site.
Keywords :
Food and Drug Administration , PTCA , FDA , DCA , percutaneous transluminal coronary angioplasty , directional coronary atherectomy , CAVEAT , Coronary Angioplasty Versus Excisional Atherectomy Trial
Journal title :
JACC (Journal of the American College of Cardiology)
Serial Year :
1998
Journal title :
JACC (Journal of the American College of Cardiology)
Record number :
480542
Link To Document :
بازگشت